The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Ranibizumab for Neovascular Age-Related Macular Degeneration
Open accessAbstract
BACKGROUND: Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration. METHODS: In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular degeneration with either minimally classic or occult (with no classic lesions) choroidal neovascularization to receive 24 monthly intravitreal injections of ranibizumab (either 0.3 mg or 0.5 mg) or sham injections. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: We enrolled 716 patients in the study. At 12 months, 94.5% of the group given 0.3 mg of ranibizumab and 94.6% of those given 0.5 mg lost fewer than 15 letters, as compared with 62.2% of patients receiving sham injections (P<0.001 for both comparisons). Visual acuity improved by 15 or more letters in 24.8% of the 0.3-mg group and 33.8% of the 0.5-mg group, as compared with 5.0% of the sham-injection group (P<0.001 for both doses). Mean increases in visual acuity were 6.5 letters in the 0.3-mg group and 7.2 letters in the 0.5-mg group, as compared with a decrease of 10.4 letters in the sham-injection group (P<0.001 for both comparisons). The benefit in visual acuity was maintained at 24 months. During 24 months, presumed endophthalmitis was identified in five patients (1.0%) and serious uveitis in six patients (1.3%) given ranibizumab. CONCLUSIONS: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration. (ClinicalTrials.gov number, NCT00056836 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ranibizumab anti-Fab immunoreactivity in treatment-naïve patients was between 0–0.9% in the MARINA and ANCHOR trials [30, 31].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regardless of anti-VEGF agent, pre-treatment ADA titers have not been shown to have any clinically relevant difference in BCVA outcomes [30, 33, 41, 43].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Repeated intravitreal (IVT) injections of anti-VEGF therapies effectively slow vision loss in the majority of treatment-compliant patients with wet AMD. 7 – 13”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ANCHOR and MARINA studies, 8-14% of eyes gained 415 letters during months 4 to 12. [22][23][24]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [22]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is now accepted that the best outcomes with anti-VEGF therapies in n-AMD are achieved with regular dosing at specific intervals, usually monthly, as demonstrated in the pivotal trials of ranibizumab, and sometimes two monthly in the first year with aflibercept after the ' three monthly initiation doses'.[22][23][24][25]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, this initial response at month 4 is not always predictive of long-term VA gains, as a proportion of such eyes continue to accrue gains in vision even after month 4 as in the ANCHOR and MARINA studies, 22,24 HARBOR study 30 and subsequent case series.31”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Other major anti-VEGF clinical trials excluded such patients.18,19,20”
From Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials (2018) · cites this paper as [19]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, such lesions may be difficult to categorise as there are a group of 'delayed responders' who will not gain vision until well after 3 and sometimes not until after 12 months.22,24”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“In CATT and all randomized clinical trials of anti-VEGF treatment for neovascular AMD, most of the improvement in mean visual acuity from baseline occurred within the first 3 to 6 months with little erosion of the benefit through 2 years when a fixed schedule of monthly (ranibizumab, bevacizumab, aflibercept) or bi-monthly (aflibercept) treatment was maintained.1,7,9,17,34”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [1]
In the citing paper
“was associated with a remarkable proportion of patients with an improvement in vision”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“Ranibizumab is a fragment of a monoclonal antibody that binds to and inhibits all forms of VEGF-A.164,165”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“This drug, when injected intravitreally on a monthly basis, prevented vision loss”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“These benefits persisted through 24 months of follow-up.”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“Mean differences in visual acuity score in the treated and control groups were also impressive, with a mean increase of seven letters in the treated group compared with a mean decrease of 10 letters in the placebo group (p<0·001).”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“At 12 months, 95% of patients given ranibizumab 0·5 mg lost fewer than 15 letters (three lines of vision) compared with 62% of the placebo group (p<0·001).”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“for the first time with any treatment for age-related macular degeneration, was associated with a remarkable proportion of patients with an improvement in vision”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“Additionally, 34% of this group improved by 15 or more letters of vision compared with the 5% in the placebo group (p<0·001).”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“The adverse effects included endophthalmitis (1%) and serious uveitis (1%).”
From Age-related macular degeneration (2008) · cites this paper as [164]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,788
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Self-citationAltman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Prevalence of Age-Related Macular Degeneration in the United States
The Eye Diseases Prevalence Research Group* (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,774
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group (1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Research works printed but not linked: 5
- Resnikoff S, 2004, Bull World Health Organ, 82, 844
- Bressler NM, 2001, Arch Ophthalmol, 119, 198
- Lopez PF, 1996, Invest Ophthalmol Vis Sci, 37, 855
- Kvanta A, 1996, Invest Ophthalmol Vis Sci, 37, 1929
- Grading of vitreous cells. In: Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: fundamentals and clinical practice. 2nd ed. New York: Mosby, 1996:64.
Cited by
Sorted by citations
Items 701–800 of 1,051
The potential of oligonucleotides for therapeutic applications
Fichou, Y., & Férec, C. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.10.003 · Cited by 90
Sayanagi, K., Sharma, S. K., Yamamoto, T., & Kaiser, P. K. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.11.002 · Cited by 90
Self-citationProgress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems
Jiang, F., Liu, B., Lu, J. G., Li, F., Li, D., Liang, C., Dang, L., Liu, J., He, B., Shaikh, A. B., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161023784 · Cited by 90
Bhisitkul, R. B., Desai, S. J., Boyer, D. S., Sadda, S. R., & Zhang, K. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.033 · Cited by 90
Self-citationRosenfeld, P. J. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19969 · Cited by 90
Self-citationda Silva, R. M., Axer‐Siegel, R., Eldem, B., Guymer, R. H., Kirchhof, B., Papp, A., Seres, A., Gekkieva, M., Nieweg, A., & Pilz, S. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.026 · Cited by 89
Bressler, N. M., Boyer, D. S., Williams, D. F., Butler, S. M., Francom, S. F., Brown, B., Nucci, F. D., Cramm, T., Tuomi, L. L., Ianchulev, T., et al. (2012) · Retina · doi:10.1097/iae.0b013e31825db6ba · Cited by 89
Self-citationLai, T. Y. Y., Chan, W., LIU, D. T. L., & Lam, D. S. C. (2009) · Retina · doi:10.1097/iae.0b013e31819ed6bd · Cited by 89
Wykoff, C. C., Brown, D. M., Maldonado, M. E., & Croft, D. E. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304736 · Cited by 89
Self-citationSustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles
Tsujinaka, H., Fu, J., Shen, J., Yu, Y., Hafiz, Z., Kays, J. C., McKenzie, D. A., Cardona, D., Culp, D., Peterson, W. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14340-x · Cited by 89
VEGF is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons
Froger, N., Matonti, F., Roubeix, C., Forster, V., Ivković, I., Brunel, N., Baudouin, C., Sahel, J., & Picaud, S. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-68488-z · Cited by 89
Hussain, R. M., Shaukat, B. A., Ciulla, L. M., Berrocal, A. M., & Sridhar, J. S. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s295223 · Cited by 89
Khanani, A. M., Guymer, R. H., Basu, K., Boston, H., Heier, J. S., Korobelnik, J., Kotecha, A., Lin, H., Silverman, D. G., Swaminathan, B., et al. (2021) · Ophthalmology Science · doi:10.1016/j.xops.2021.100076 · Cited by 89
Self-citationHypoxia-Inducible Factor (HIF)/Vascular Endothelial Growth Factor (VEGF) Signaling in the Retina
Kurihara, T., Westenskow, P. D., & Friedlander, M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3209-8_35 · Cited by 89
Chan, W., Lai, T. Y. Y., Chan, K. M., Li, H., LIU, D. T. L., Lam, D. S. C., & Pang, C. (2008) · Retina · doi:10.1097/iae.0b013e31818358b2 · Cited by 89
Nutritional modulation of age-related macular degeneration
Weikel, K., Chiu, C., & Taylor, A. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.03.005 · Cited by 89
Low-Fluence Photodynamic Therapy versus Ranibizumab for Chronic Central Serous Chorioretinopathy
Bae, S. H., Heo, J., Kim, C., Kim, T. W., Shin, J. Y., Lee, J. Y., Song, S. J., Park, T. K., Moon, S. W., & Chung, H. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.024 · Cited by 89
Wang, Y., He, Y.-G., Mitzel, G. M., Zhang, S., & Bartlett, M. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12037 · Cited by 89
Monoclonal antibodies: technologies for early discovery and engineering
Kennedy, P. J., Oliveíra, C., Granja, P. L., & Sarmento, B. F. C. C. (2017) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1357002 · Cited by 89
Holekamp, N. M., Liu, Y., Yeh, W.-S., Chia, Y., Kiss, S., Almony, A., & Kowalski, J. W. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.12.018 · Cited by 88
Arcinue, C. A., Ma, F., Barteselli, G., Sharpsten, L., Gomez, M. L., & Freeman, W. R. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.11.022 · Cited by 88
Chandra, S., Arpa, C., Menon, D., Khalid, H., HAMILTON, R. D., Nicholson, L., Pal, B., Fasolo, S., Hykin, P. G., Keane, P. A., et al. (2020) · Eye · doi:10.1038/s41433-020-0764-9 · Cited by 88
Holmberg, O., Köhler, N., Martins, T. G. D. S., Siedlecki, J., Herold, T., Keidel, L. F., Asani, B., Schiefelbein, J. B., Priglinger, S. G., Kortuem, K., et al. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-00247-1 · Cited by 88
Lois, N., McBain, V. A., Abdelkader, E., SCOTT, N. W., & Kumari, R. (2012) · Retina · doi:10.1097/iae.0b013e3182657fff · Cited by 88
Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
Folk, J. C., & Stone, E. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmct1000495 · Cited by 88
Xie, B., Shen, J., Dong, A., Rashid, A., STOLLER, G. L., & Campochiaro, P. A. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21588 · Cited by 88
Liakopoulos, S., Ongchin, S. C., Bansal, A. S., Msutta, S., Walsh, A. C., Updike, P. G., & Sadda, S. R. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-1877 · Cited by 88
Gammons, M. V. R., Fedorov, O., Ivison, D., Du, C., Clark, T., Hopkins, C., Hagiwara, M., Dick, A. D., Cox, R. J., Harper, S. J., et al. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12422 · Cited by 88
London, N. J. S., Garg, S. J., Moorthy, R. S., & Cunningham, E. T. (2013) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/1869-5760-3-43 · Cited by 88
Ritter, M., Simader, C., Bolz, M., Deák, G. G., Sponer, U., Sayegh, R. G., Kundi, M., & Schmidt-Erfurth, U. M. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305186 · Cited by 88
Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors
Xu, K., Chin, E. K., Bennett, S. R., Williams, D. F., Ryan, E. H., Dev, S., Mittra, R. A., Quiram, P. A., Davies, J. B., Parke, D. W., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.01.022 · Cited by 88
Kamao, H., Mandai, M., Ohashi, W., Hirami, Y., Kurimoto, Y., Kiryu, J., & Takahashi, M. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19778 · Cited by 87
Nanotechnology for Medical and Surgical Glaucoma Therapy—A Review
Occhiutto, M. L., Maranhão, R. C., Costa, V. P., & Konstas, A. G. P. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01163-6 · Cited by 87
Kertes, P. J., Galic, I. J., Greve, M. D. J., Williams, G., Baker, J., Lahaie, M., & Sheidow, T. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.5540 · Cited by 87
Shimada, H., Hattori, T., Mori, R., Nakashizuka, H., Fujita, K., & Yuzawa, M. (2013) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-013-2274-y · Cited by 87
Management of retinal vascular diseases: a patient-centric approach
Brand, C. (2012) · Eye · doi:10.1038/eye.2012.32 · Cited by 87
Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration
Muether, P. S., Hoerster, R., Hermann, M. M., Kirchhof, B., & Fauser, S. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2038-0 · Cited by 87
Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy
Shen, L. Q. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.6.793 · Cited by 87
Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity
Law, J. C., Recchia, F. M., Morrison, D. G., Donahue, S. P., & Estes, R. L. (2010) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2009.10.011 · Cited by 87
Schauwvlieghe, A.-S. M. E., Dijkman, G., Hooymans, J. M. M., Verbraak, F. D., Hoyng, C. B., Dijkgraaf, M. G. W., Pető, T., Vingerling, J. R., & Schlingemann, R. O. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153052 · Cited by 87
Vedula, S. S., & Krzystolik, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub2 · Cited by 87
Wang, X., Sawada, T., Sawada, O., Saishin, Y., Liu, P., & Ohji, M. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.06.009 · Cited by 86
Pharmacotherapy for uveitis: current management and emerging therapy
Denniston, A. K., Barry, R. J., Nguyen, Q. D., Lee, R., & Murray, P. I. (2014) · Clinical ophthalmology · doi:10.2147/opth.s47778 · Cited by 86
Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery
Quinteros, D. A., Bermúdez, J. M., Ravetti, S., Cid, A. G., Allemandi, D. A., & Palma, S. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46143-6.00025-7 · Cited by 86
Woo, S. J., Veith, M., Hamouz, J., Ernest, J., Zalewski, D., Studnička, J., Vajas, A., Papp, A., Vogt, G., Luu, J. K., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.5053 · Cited by 86
Laser photocoagulation for neovascular age-related macular degeneration
Virgili, G., & Bini, A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004763.pub2 · Cited by 86
Hatz, K. B., & Prünte, C. F. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303444 · Cited by 86
VEGF-A 165 b Is Cytoprotective and Antiangiogenic in the Retina
Magnussen, A., Rennel, E., Hua, J., Bevan, H. S., Beazley‐Long, N., Lehrling, C., Gammons, M. V. R., Floege, J., Harper, S. J., Agostini, H. T., et al. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4296 · Cited by 86
Retinal Pigment Epithelial Tear Following Intravitreal Pegaptanib Sodium
Dhalla, M. S., Blinder, K. J., Tewari, A., Hariprasad, S. M., & Apte, R. S. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.10.053 · Cited by 86
BARBAZETTO, I. A., Saroj, N., Shapiro, H., Wong, P., Ho, A. C., & Freund, K. B. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.01.007 · Cited by 86
Stein, J. D., Newman-Casey, P. A., Tavag, M., Lee, P. P., & Hutton, D. W. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.037 · Cited by 85
Pharmacokinetics of Intravitreally Injected Bevacizumab in Vitrectomized Eyes
Ahn, J., Kim, H., Woo, S. J., Park, J. H., Park, S. Y., Hwang, D. D.-J., & Park, K. H. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2013.0009 · Cited by 85
Sabour‐Pickett, S., Nolan, J. M., Loughman, J., & Beatty, S. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100219 · Cited by 85
Modelling the Genetic Risk in Age-Related Macular Degeneration
Graßmann, F., Fritsche, L. G., Keilhauer, C. N., Heid, I. M., & Weber, B. H. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037979 · Cited by 85
Adam, M., Berger, C., Feldner, A., Yang, W.-J., Wüstehube‐Lausch, J., Herberich, S. E., Pinder, M., Gesierich, S., Hammes, H., Augustin, H. G., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.301686 · Cited by 85
Kertes, P. J., Galic, I. J., Greve, M. D. J., Williams, G., Rampakakis, E., Scarino, A., & Sheidow, T. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.01.013 · Cited by 85
Update on pharmacotherapy for ocular surface squamous neoplasia
Bayyat, G. J. A., Arreaza-Kaufman, D., Venkateswaran, N., Galor, A., & Karp, C. L. (2019) · Eye and Vision · doi:10.1186/s40662-019-0150-5 · Cited by 85
Wolf, A., & Kampik, A. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-013-2562-6 · Cited by 86
Dakin, H., Wordsworth, S., Rogers, C. A., Abangma, G., Raftery, J. P., Harding, S. P., Lotery, A. J., Downes, S. M., Chakravarthy, U., Reeves, B. C., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005094 · Cited by 85
Lotery, A., Griner, R., Ferreira, A., Milnes, F., & Dugel, P. (2017) · Eye · doi:10.1038/eye.2017.143 · Cited by 84
Age-related macular degeneration: The importance of family history as a risk factor
Shahid, H., Khan, J. C., Cipriani, V., Sepp, T., Matharu, B. K., Bunce, C., Harding, S. P., Clayton, D. G., Moore, A. T., Yates, J. R. W., et al. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300193 · Cited by 84
Stem cell therapy and the retina
MacLaren, R. E., & Pearson, R. A. (2007) · Eye · doi:10.1038/sj.eye.6702842 · Cited by 84
Sponer, U., Waldstein, S. M., Kundi, M., Ritter, M., Golbaz, I., Heiling, U., Papp, A., Simader, C., & Schmidt-Erfurth, U. M. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.05.032 · Cited by 84
Bracha, P., Moore, N. A., Ciulla, T. A., WuDunn, D., & Cantor, L. B. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.08.008 · Cited by 84
Lai, T., Hsieh, Y., Yang, C., Ho, T., & Yang, C. (2019) · Scientific Reports · doi:10.1038/s41598-018-36704-6 · Cited by 84
Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020
Samanta, A., Aziz, A. A., Jhingan, M., Singh, S. R., Khanani, A. M., & Chhablani, J. K. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000291 · Cited by 84
Loyet, K. M., DeForge, L. E., Katschke, K. J., Diehl, L. J., Graham, R., Pao, L. I., Sturgeon, L., Lewin-Koh, S.-C., Hollyfield, J. G., & Campagne, M. V. L. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9587 · Cited by 84
Souied, E. H., Devin, F., Mauget‐Faÿsse, M., Kolář, P., Wolf-Schnurrbusch, U. E. K., Framme, C., Gaucher, D., Querques, G., Stumpp, M. T., & Wolf, S. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.05.037 · Cited by 84
Xue, Y., Lim, S., Bråkenhielm, E., & Cao, Y. (2010) · Nature Protocols · doi:10.1038/nprot.2010.46 · Cited by 84
Gologorsky, D., Thanos, A., & Vavvas, D. G. (2012) · Mediators of Inflammation · doi:10.1155/2012/629452 · Cited by 84
Progression of Geographic Atrophy and Genotype in Age-Related Macular Degeneration
Klein, M. L., Ferris, F. L., Francis, P. J., Lindblad, A. S., Chew, E. Y., Hamon, S., & Ott, J. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.12.012 · Cited by 84
Hsu, J., Gerstenblith, A. T., Garg, S. J., & VANDER, J. F. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.10.003 · Cited by 84
Abedi, F., Wickremasinghe, S., Richardson, A. J., Makalic, E., Schmidt, D. F., Sandhu, S. S., Baird, P. N., & Guymer, R. H. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.006 · Cited by 84
Current therapeutic developments in atrophic age-related macular degeneration
Hanus, J., Zhao, F., & Wang, S. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-306972 · Cited by 84
Vascular Endothelial Cell Growth Factor-A
D'Amore, P. A. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070385 · Cited by 84
Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Agrawal, S., Joshi, M., & Christoforidis, J. B. (2013) · Mediators of Inflammation · doi:10.1155/2013/943409 · Cited by 83
INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF INFLAMMATORY CHOROIDAL NEOVASCULARIZATION
Rouvas, A., Petrou, P., Douvali, M., Ntouraki, A., Vergados, I. A., Georgalas, I., & Markomichelakis, N. (2011) · Retina · doi:10.1097/iae.0b013e3182003ca8 · Cited by 83
ENDOPHTHALMITIS ASSOCIATED WITH INTRAVITREAL INJECTIONS
Tabandeh, H., Boscia, F., Sborgia, A., Ciracì, L., Dayani, P. N., Mariotti, C., Furino, C., & Flynn, H. W. (2013) · Retina · doi:10.1097/iae.0000000000000008 · Cited by 83
Lukason, M., DuFresne, E., Rubin, H. L., Pechan, P. A., Li, Q., Kim, I. K., Kiss, S., Flaxel, C. J., Collins, M., Miller, J. W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.230 · Cited by 83
Brown, M. M., Brown, G. C., Brown, H. C., & Peet, J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.08.033 · Cited by 83
Lai, T. Y. Y., Lee, G. K. Y., Luk, F. O. J., & Lam, D. S. C. (2011) · Retina · doi:10.1097/iae.0b013e31820d3f3f · Cited by 82
Hsu, M., Yang, C., Hsu, W.-H., Lin, K., Wang, C.-Y., Shen, Y.-C., Chen, Y., Chau, S.-F., Tsai, H.-Y., & Cheng, C. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.01.030 · Cited by 82
Chakravarthy, U., Bailey, C., Brown, D. M., Campochiaro, P. A., Chittum, M. E., Csaky, K. G., Tufail, A., Yates, P., Cech, P. G., Giraudon, M., et al. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.03.003 · Cited by 82
Self-citationOkada, M., Kandasamy, R., Chong, E. W. T., McGuiness, M. B., & Guymer, R. H. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.05.026 · Cited by 82
Mitchell, P., Annemans, L., Gallagher, M., Hasan, R., Thomas, S. K., Gairy, K., Knudsen, M. S., & Konwea, H. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300726 · Cited by 82
Chang, L. K. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.7.941 · Cited by 82
Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept
Dias, J. R. D. O., de Andrade, G. C., Novais, E. A., Farah, M. E., & Rodrigues, E. B. (2016) · International Journal of Retina and Vitreous · doi:10.1186/s40942-016-0026-y · Cited by 82
SUSTAINED ELEVATION OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL ANTI-VEGF AGENTS
Dedania, V. S., & Bakri, S. J. (2015) · Retina · doi:10.1097/iae.0000000000000520 · Cited by 82
Drug delivery devices for retinal diseases
Kaji, H., Nagai, N., Nishizawa, M., & Abe, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.002 · Cited by 82
Broadhead, G., Grigg, J., McCluskey, P., Hong, T., Schlub, T. E., & Chang, A. (2018) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-018-4163-x · Cited by 82
Moorthy, R. S., Moorthy, M. S., & Cunningham, E. T. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000530 · Cited by 82
Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
Georgalas, I., Perganta, Vakalis, Vachtsevanos, Tranos, Asteriades, S., & Koukoula (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s43470 · Cited by 81
Gianniou, C., Dirani, A., Jang, L., & Mantel, I. (2015) · Retina · doi:10.1097/iae.0000000000000465 · Cited by 81
Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
Angelbello, A. J., Chen, J. L., Childs‐Disney, J. L., Zhang, P., Wang, Z.-F., & Disney, M. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00504 · Cited by 81
Bailey, S. T., Thaware, O. C., Wang, J., Hagag, A. M., Zhang, X., Flaxel, C. J., Lauer, A. K., Hwang, T. S., Lin, P., Huang, D., et al. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.03.008 · Cited by 81
Fernandes, A. R., Zielińska, A., Sánchez‐López, E., dos Santos, T., García, M. L., Silva, A. M., Karczewski, J., & Souto, E. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052592 · Cited by 82
Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection
Artunay, Ö., Yuzbasioglu, E., Rasier, R., Şengül, E. A., & Bahçecıoğlu, H. (2009) · Eye · doi:10.1038/eye.2009.7 · Cited by 81
Wen, H., Hao, J., & Li, S. K. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23387 · Cited by 81
DeCroos, F. C., Reed, D. C., Adam, M. K., Salz, D. A., Gupta, O. P., Ho, A. C., & Regillo, C. D. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.06.002 · Cited by 81
Blick, S. K. A., Keating, G. M., & Wagstaff, A. J. (2007) · Drugs · doi:10.2165/00003495-200767080-00007 · Cited by 81
Metadata
- Authors
- Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y.
- Affiliations
- University of Miami (US)
- Houston Methodist (US)
- Ophthalmic Consultants of Boston (US)
- Retina Vitreous Associates Medical Group (US)
- Cleveland Clinic (US)
- Genentech (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-05
- Volume
- 355
- Issue
- 14
- Pages
- 1419-1431
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2124415048
- Cited by
- 5,886
- References
- 25
- Citations by year
- 2026: 179 · 2025: 231 · 2024: 207 · 2023: 198 · 2022: 242 · 2021: 324 · 2020: 311 · 2019: 259 · 2018: 286 · 2017: 325 · 2016: 313 · 2015: 356 · 2014: 358 · 2013: 371 · 2012: 371
- FWCI
- 240.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Pennsylvania State University
- University of South Florida
- Towson University
- Genentech
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, neovascular age-related macular degeneration, choroidal neovascularization, intravitreal injection, anti-VEGF therapy, VEGF-A, visual acuity, blindness prevention, endophthalmitis, uveitis, adverse events, long-term follow-up, dose comparison, occult choroidal neovascularization, anti-angiogenic therapy, VEGF inhibitors
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Optic Disk, Visual Acuity, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
